Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

CorMedix Therapeutics: Portfolio Diversification Supports Growth Amid Reimbursement Pressure

Nov 19, 2026 | Team Kalkine
CorMedix Therapeutics: Portfolio Diversification Supports Growth Amid Reimbursement Pressure
Image source: shutterstock

  • CRMD:NASDAQ
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (US$)

CorMedix Inc

CorMedix Inc (NASDAQ: CRMD) is a biopharmaceutical company focused on developing and commercializing therapies for life-threatening conditions. Its lead product, DefenCath, is an antimicrobial catheter lock solution that reduces catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter. Its commercial portfolio also includes anti-infective therapies MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA and KIMYRSA, alongside TOPROL-XL.

Financial Performance and Earnings Quality


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…